Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1996-03-08
2000-01-11
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424467, 424465, 424490, 424475, 424469, 514925, A61K 922, A61K 930
Patent
active
060132817
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention refers to new pharmaceutical formulations comprising acid labile heterocyclic compounds with gastric inhibitory effect, in the following referred to as proton pump inhibitors. The new formulations are intended for oral use. Furthermore, the present invention refers to a new method for the manufacture of such a formulation and, the use of the new formulations in medicine.
BACKGROUND OF THE INVENTION
The proton pump inhibitors are for example compounds of the general formula I ##STR1## wherein Het.sub.1 is ##STR2## Het.sub.2 is ##STR3## X= ##STR4## wherein N in the benzimidazole moiety means that one of the carbon atoms substituted by R.sub.6 -R.sub.9 optionally may be exchanged for a nitrogen atom without any substituents; hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy, alkyl and aralkyl; alkyl alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl trifluoroalkyl, or adjacent groups R.sub.6 -R.sub.9 form ring structures which may be further substituted; halogen or alkyl or, alkoxy groups. In the above definitions, alkyl groups, alkoxy groups, and moieties thereof may be branched and straight C.sub.1 -C.sub.9 -chains or comprise cyclic alkyl groups, for example cycloalkylalkyl.
Examples of proton pump inhibitors according to formula I are ##STR5##
The proton pump inhibitors used in the dosage forms of the invention may be used in neutral form or in the form of an alkaline salt, such as for instance the Mg.sup.2+, Ca.sup.2+, Na.sup.+, K.sup.+ or Li.sup.+ salts, preferably the Mg.sup.2+ salts. Further where applicable, the compounds listed above may be used in racemic form or in the form of a substantially pure enantiomer thereof, or alkaline salts of the racemates or the single enantiomers.
Suitable proton pump inhibitors are for example disclosed in EP-A1-0005129, EP-A1-174 726, EP-A1-166 287, GB 2 163 747 and WO90/06925, WO91/19711, WO91/19712, and further especially suitable compounds are described in WO94/27988 and WO95/01977.
These proton pump inhibitors are, as already mentioned, useful for inhibiting gastric acid secretion in mammals and man. In a more general sense, they may be used for prevention and treatment of gastric-acid related diseases in mammals and man, including e.g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. They may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre- and postoperatively to prevent aspiration of gastric acid and to prevent and treat stress ulceration. Further, they may be useful in the treatment of Helicobacter infections and diseases related to these.
These proton pump inhibitors are, however, susceptible to degradation/transformation in acidic reacting and neutral media The degradation is catalyzed by acidic reacting compounds and the proton pump inhibitors are usually stabilized in mixtures with alkaline reacting compounds.
In respect to the stability properties of the proton pump inhibitors mentioned above, it is obvious that a proton pump inhibitor in an oral solid dosage form must be protected from contact with the acidic reacting gastric juice and the active substance must be transferred in intact form to that part of the gastrointestinal tract where pH is less acidic, neutral or alkaline and where rapid absorption of the pharmaceutically active substance, i.e. the proton pump inhibitor, can occur.
A pharmaceutical dosage form of these proton pump inhibitors is best protected from contact with acidic gastric juice by an enteric coating layer. In U.S. Pat. No. 4,853,230 such enteric coated preparations of d
REFERENCES:
patent: 4628098 (1986-12-01), Nohara et al.
patent: 4758579 (1988-07-01), Kohl et al.
patent: 4786505 (1988-11-01), Lovgren et al.
patent: 4786650 (1988-11-01), Lovgren et al.
patent: 4853230 (1989-08-01), Lovgren et al.
patent: 5026560 (1991-06-01), Makino et al.
patent: 5045321 (1991-09-01), Makino et al.
patent: 5093132 (1992-03-01), Makino et al.
patent: 5232706 (1993-08-01), Palomo Coll
patent: 5626875 (1997-05-01), Ballester Rodes
patent: 5690960 (1997-11-01), Bengtsson et al.
patent: 5753265 (1998-05-01), Bergstrand et al.
patent: 5817338 (1998-10-01), Bergstrand et al.
Sih et al., Studies on (H+ K+ )--ATPase Inhibitors of Gastric Secretion, J. Med. Chem. 34(3) pp. 1049-1062, 1991.
Lovgren Kurt
Lundberg Per Johan
Astra Aktiebolag
Page Thurman K.
Seidleck Brian K.
LandOfFree
Method of making a pharmaceutical dosage form comprising a proto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of making a pharmaceutical dosage form comprising a proto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of making a pharmaceutical dosage form comprising a proto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1460002